Anido Herranz, UrbanoFernández Calvo, OvidioAfonso Afonso, Francisco JavierRodríguez Martínez de Llano, SofíaLázaro Quintela, MartínLeón Mateos, LuisVázquez Estévez, SergioAntón-Aparicio, Luis M.2019-02-272019-02-272015-01-02Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, et al. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015; 15(3):339-3481473-7140http://hdl.handle.net/2183/21994Review[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to demonstrate an improvement in overall survival and time to first symptomatic skeletal event in patients with castration resistant prostate cancer with symptomatic bone metastases. This fact has created a new paradigm in the treatment of prostate cancer landscape, where only chemotherapy and hormone therapy had a role, while β-emitters had been confined exclusively to the role of pain relief with no impact on survival. The aim of this review is to outline current treatment approaches for advanced prostate cancer with a focus on the role of radium-223 dichloride, reviewing patients' profile that make them suitable to therapy and chances for further studies.engThis is an accepted manuscript of an article published by Taylor & Francis in Expert Rev Anticancer Ther, avaliable at Taylor & Francis Online.Alpha-emittersBone metastasesProstate cancerRadiopharmaceuticalsRadium-223journal articleopen access